It’s been a rough year for Bruce Linton. After being terminated last July as co-CEO of Canopy Growth Corp (TSX: WEED) (NYSE: CGC), a company he helped found, Linton has now seen his employment terminated with that of Vireo Health (CSE: VREO), where he served as executive chairman.
Linton was originally appointed to the position last November after making a large show of where he would elect to take a position. Compensation in total amounted to 15 million compensation warrants with an exercise price ranging US$1.02 to that of US$5.86.
Originally the warrants were to vest over a period of two years, however it is believed that has been bumped up now. Any compensation warrants that have been issued, which originally had an expiration of November 7, 2024, have now been modified to expire June 8, 2021.
Linton’s employment was terminated on an entirely without-cause basis, effective immediately. Justification for his termination was not provided by Vireo. The company has no current plans to obtain a replacement for the position.
Vireo Health last traded at $0.91 on the CSE.
Information for this briefing was found via Sedar and Vireo Health. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.